GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Morphic Holding Inc (NAS:MORF) » Definitions » 10-Year RORE %

Morphic Holding (Morphic Holding) 10-Year RORE % : 0.00% (As of Mar. 2024)


View and export this data going back to 2019. Start your Free Trial

What is Morphic Holding 10-Year RORE %?

Return on Retained Earnings (RORE) is an indicator of a company's growth potential, it shows how much a company earns by reinvesting its retained earnings, i.e. profits after dividend payments. Morphic Holding does not have enough data to calculate 10-Year RORE %.


Morphic Holding 10-Year RORE % Historical Data

The historical data trend for Morphic Holding's 10-Year RORE % can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Morphic Holding 10-Year RORE % Chart

Morphic Holding Annual Data
Trend Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
10-Year RORE %
Get a 7-Day Free Trial - - - - -

Morphic Holding Quarterly Data
Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24
10-Year RORE % Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only - - - - -

Competitive Comparison of Morphic Holding's 10-Year RORE %

For the Biotechnology subindustry, Morphic Holding's 10-Year RORE %, along with its competitors' market caps and 10-Year RORE % data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Morphic Holding's 10-Year RORE % Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Morphic Holding's 10-Year RORE % distribution charts can be found below:

* The bar in red indicates where Morphic Holding's 10-Year RORE % falls into.



Morphic Holding 10-Year RORE % Calculation

Morphic Holding's 10-Year RORE % for the quarter that ended in Mar. 2024 is calculated as:

10-Year RORE %=( Most Recent EPS (Diluted)- First Period EPS (Diluted) )/( Cumulative EPS (Diluted) for 10-year -Cumulative Dividends per Share for 10-year )
=( - )/( - )
=/
=N/A %

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

In the calculation of 10-Year RORE %, the most recent and first period EPS (Diluted) is the trailing twelve months (TTM) data ended in Mar. 2024 and 10-year before.


Morphic Holding  (NAS:MORF) 10-Year RORE % Explanation

Return on Retained Earnings (RORE) is important to investors because it reveals a company's efficiency and growth potential. A higher RORE indicates a higher return. A high RORE indicates that the company should reinvest profits into the business. A lower RORE suggests that the company should distribute profits to shareholders by paying out dividends, since those dollars aren't generating much additional growth for the company.

There are a several different ways to arrive at the Return on Retained Earnings. The simplest way to calculate it is by using published information on Earnings per Share (EPS) and Dividend per Share (DPS) over a selected period. Here, 10-year period is chosen.

Be Aware

Please keep in mind that the RORE is relative to the nature of the business and its competitors. If another company in the same sector is producing a lower return on retained earnings, it doesn’t necessarily mean it’s a bad investment. It may just suggest the company is older and no longer in a high growth stage. At such a stage in the business cycle, it would be expected to see a lower RORE and higher dividend payout.


Morphic Holding 10-Year RORE % Related Terms

Thank you for viewing the detailed overview of Morphic Holding's 10-Year RORE % provided by GuruFocus.com. Please click on the following links to see related term pages.


Morphic Holding (Morphic Holding) Business Description

Traded in Other Exchanges
Address
35 Gatehouse Drive, A2, Waltham, MA, USA, 02451
Morphic Holding Inc is a biopharmaceutical company applying its insights into integrins to discover and develop a pipeline of oral small-molecule integrin therapeutics. Integrins are a target class with multiple approved injectable blockbuster drugs for the treatment of serious chronic diseases, including autoimmune, cardiovascular, and metabolic diseases, fibrosis, and cancer.
Executives
William Devaul officer: General Counsel and Secretary C/O MORPHIC HOLDING, INC., 35 GATEHOUSE DRIVE, A2, WALTHAM MA 02451
Bruce Rogers officer: Chief Scientific Officer C/O MORPHIC HOLDING, INC., 35 GATEHOUSE DRIVE, A2, WALTHAM MA 02451
Marc Schegerin officer: CFO and COO ARQULE INC, 1 WALL ST FL6, BURLINGTON MA 01803
Praveen P. Tipirneni director, officer: President and CEO C/O MORPHIC HOLDING, INC.,, 35 GATEHOUSE DRIVE, A2, WALTHAM MA 02451
Farrell Robert E Jr officer: VP Finance and Ops, Secretary CAMBRIDGE DISCOVERY PARK, 100 ACORN PARK DRIVE, 5TH FLOOR, CAMBRIDGE MA 02140
Joseph P Slattery director C/O TRANSENTERIX, INC., 635 DAVIS DRIVE, SUITE 300, MORRISVILLE NC 27560
Martin Edwards director 15 NEW ENGLAND EXECUTIVE PARK, BURLINGTON MA 01803
Timothy A Springer director, 10 percent owner 36 WOODMAN ROAD, CHESTNUT HILL MA 02467
Peter Linde officer: Chief Medical Officer C/O MORPHIC HOLDING, INC., 35 GATEHOUSE DRIVE A2, WALTHAM ME 02451
Nisha Nanda director 281 TRESSER BOULEVARD, STAMFORD CT 06901
Amir Nashat director 10835 ROAD TO THE CURE, SUITE 205, SAN DIEGO CA 92121
Omega Fund V Gp, L.p. director 888 BOYLSTON ST., SUITE 1111, BOSTON MA 02199
Susannah Gray director 10770 WATERIDGE CIRCLE SUITE 200, SAN DIEGO CA 92121
Vikas Goyal director C/O SR ONE, LTD., 161 WASHINGTON ST., SUITE 500, EIGHT TOWER BRIDGE, CONSHOHOCKEN PA 19428
Otello Stampacchia director 888 BOYLSTON ST., SUITE 1111, BOSTON MA 02199

Morphic Holding (Morphic Holding) Headlines

From GuruFocus